Yaron Shoham

Dr. Yaron Shoham

Plastic Surgery Department and Burn Unit, Soroka University Medical Center, Faculty of Health Sciences, Ben Gurion University of the Negev, Beer Sheba, Israel
orcid

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 July 2023 in International Wound Journal
Verified
Journal Article
Open access
Yaron ShohamYaron Shoham
Yaron Shoham
Konstantinos GasteratosKonstantinos Gasteratos
Konstantinos Gasteratos
ASAdam J. Singer
Adam J. Singer
YKYuval Krieger
Yuval Krieger
ESEldad Silberstein
Eldad Silberstein
JGJeremy Goverman
Jeremy Goverman
In 2012 the European Medicines Agency approved a pineapple stem‐derived Bromelain‐based debridement concentrate of proteolytic enzymes (NexoBrid®, MediWound Ltd, Yavne, Israel) for adult deep burns. Over 10 000 patients have been successfully treated with NexoBrid® globally, including in the US. The aim of our study is to perform a systematic review of the current literature on Nexobrid® outcomes. We conducted a literature search in PubMed, Google Scholar, Embase, and other search engines (2013–2023). The online screening process was performed by two independent reviewers with the Covidence tool. The protocol was reported using the Preferred Reporting Items for Systematic Review and Meta‐Analyses, and it was registered at the International Prospective Register of Systematic Reviews of the National Institute for Health Research. We identified 103 relevant studies of which 34 were found eligible. The included studies report the positive effects of Nexobrid® on burn debridement, functional and cosmetic outcomes, scarring, and quality of life. Also, they validate the high patient satisfaction thanks to enhanced protocols of analgosedation and/or locoregional anaesthesia during Bromelain‐based debridement. Two studies investigate potential risks (coagulopathy, burn wound infection) which concluded there is no strong evidence of these adverse events. NexoBrid® is a safe, selective, non‐surgical eschar removal treatment modality. The benefits of Bromelain‐based debridement are faster debridement and healing times, reduced operations, length of stay, cases of sepsis, blood transfusions, and prevention of compartment syndrome. Existing evidence suggests that the indications and the role of Bromelain‐based debridement are expanding to cover “off‐label” cases with significant benefits to the global healthcare economy.

16 September 2023 in Journal of Burn Care & Research
Verified
Journal Article
Closed access
PDF file
Yaron ShohamYaron Shoham
Yaron Shoham
LRLior Rosenberg
Lior Rosenberg
WHWilliam Hickerson
William Hickerson
JGJeremy Goverman
Jeremy Goverman
NINarayan Iyer
Narayan Iyer
ASAdam J Singer
Adam J Singer
Since 1970 surgeons have managed deep burns by surgical debridement and autografting. We tested the hypothesis that enzymatic debridement with NexoBrid would remove the eschar reducing surgery and achieve comparable long-term outcomes as standard of care (SOC). In this Phase 3 trial, we randomly assigned adults with deep burns (covering 3–30% of total body surface area [TBSA]) to NexoBrid, surgical or nonsurgical SOC, or placebo Gel Vehicle (GV) in a 3:3:1 ratio. The primary endpoint was complete eschar removal (ER) at the end of the debridement phase. Secondary outcomes were need for surgery, time to complete ER, and blood loss. Safety endpoints included wound closure and 12 and 24-months cosmesis on the Modified Vancouver Scar Scale. Patients were randomized to NexoBrid (n = 75), SOC (n = 75), and GV (n = 25). Complete ER was higher in the NexoBrid versus the GV group (93% vs 4%; P < .001). Surgical excision was lower in the NexoBrid vs the SOC group (4% vs 72%; P < .001). Median time to ER was 1.0 and 3.8 days for the NexoBrid and SOC respectively (P < .001). ER blood loss was lower in the NexoBrid than the SOC group (14 ± 512 mL vs 814 ± 1020 mL, respectively; P < .0001). MVSS scores at 12 and 24 months were noninferior in the NexoBrid versus SOC groups (3.7 ± 2.1 vs 5.0 ± 3.1 for the 12 months and 3.04 ± 2.2 vs 3.30 ± 2.76 for the 24 months). NexoBrid resulted in early complete ER in >90% of burn patients, reduced surgery and blood loss. NexoBrid was safe and well tolerated without deleterious effects on wound closure and scarring.

25 April 2018 in International Wound Journal
Verified
Journal Article
Closed access
PDF file
Yaron ShohamYaron Shoham
Yaron Shoham
YKYuval Krieger
Yuval Krieger
ETEran Tamir
Eran Tamir
ESEldad Silberstein
Eldad Silberstein
ABAlexander Bogdanov‐Berezovsky
Alexander Bogdanov‐Berezovsky
LRLior Rosenberg
Lior Rosenberg

7 July 2021 in Wound Repair and Regeneration
Verified
Journal Article
Closed access
PDF file
Yaron ShohamYaron Shoham
Yaron Shoham
ESEyal Shapira
Eyal Shapira
JHJosef Haik
Josef Haik
MHMoti Harats
Moti Harats
DEDana Egozi
Dana Egozi
ASAvshalom Shalom
Avshalom Shalom

22 May 2020 in International Wound Journal
Verified
Journal Article
Closed access
PDF file
Yaron ShohamYaron Shoham
Yaron Shoham
Yuval KriegerYuval Krieger
Yuval Krieger
GRGuy Rubin
Guy Rubin
IKIngo Koenigs
Ingo Koenigs
BHBernd Hartmann
Bernd Hartmann
ESEldad Silberstein
Eldad Silberstein

22 June 2014 in BioMed Research International
Verified
Journal Article
Open access
PDF file
Yaron ShohamYaron Shoham
Yaron Shoham
YKYuval Krieger
Yuval Krieger
ZPZvi Howard Perry
Zvi Howard Perry
GSGad Shaked
Gad Shaked
ABAlexander Bogdanov-Berezovsky
Alexander Bogdanov-Berezovsky
ADAmos Douvdevani
Amos Douvdevani
Background. Despite great advances in the treatment of burn patients, useful prognostic markers are sparse. During the past years there has been increasing interest in circulating plasma cell free DNA as a potential marker for tissue injury. We have developed a rapid direct fluorescent assay for cell free DNA quantification that allows obtaining accurate, fast, and inexpensive measurements.Objective. To use this technique for measuring plasma cell free DNA levels in burn patients and to further explore the use of cell free DNA as a potential marker of patient outcome in burns.Methods. Cell free DNA levels obtained from 14 burn victims within 6 hours of injury and 14 healthy controls were quantified by a direct rapid fluorometric assay.Results. Patient admission cell free DNA levels were significantly elevated compared with that of controls (1797 ± 1523 ng/mL versus 374 ± 245 ng/mL,P=0.004). There are statistically significant correlations between cell free DNA admission levels and burn degree (Spearman’s correlation = 0.78,P=0.001), total body surface area (Spearman’s correlation = 0.61,P=0.02), and total burn volume (Spearman’s correlation = 0.64,P=0.014).Conclusions. Admission cell free DNA levels can serve as a prognostic factor in burns and future routine use can be made possible by use of our direct rapid fluorometric assay.